Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort
Abstract Introduction Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric symptoms have not been systemically quantified using structured scal...
I tiakina i:
| Ngā kaituhi matua: | , , , , , , , , , , , , |
|---|---|
| Hōputu: | Artigo |
| Reo: | Inglês |
| I whakaputaina: |
BMC
2020-01-01
|
| Rangatū: | AIDS Research and Therapy |
| Ngā marau: | |
| Urunga tuihono: | https://doi.org/10.1186/s12981-019-0257-8 |
| Ngā Tūtohu: |
Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!
|